Select your location
We have detected that you are here: Switzerland.
You will be redirected to the website for: SCHILLER Sales Switzerland
in: English.
Would you like to see the content for another country or in another language?
HyperQ Stress
Revolutionising the detection of coronary artery disease
Coronary Artery Disease (CAD) screening is largely based on exercise ECG testing that has a limited diagnostic accuracy, especially in women. Additionally, there are growing concerns over exposure to radiation and cutbacks on payment for costly cardiac imaging.
HyperQ Stress ECG testing provides a low-cost, non-invasive, radiation-free and highly reliable first line CAD diagnostic solution for private cardiology practices as well as cardiology departments in hospitals. HyperQ is based on solid scientific and clinical research.
Features
- Higher sensitivity in diagnosing ischaemia
- Fewer false alarms in non-ischaemic patients
- Performs equally well in women and men
- Provides clear results in patients with equivocal standard exercise ECG test results
SCHILLER reserves the right to make changes in design, specifications and features shown, or discontinue the product described at any time without notice or obligation. Images may be representative. Device availability in your market is subject to regulatory approval.
